Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030
Surgical Laser Market Growth & Trends
The global surgical laser market size is anticipated to reach USD 15.96 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.6% from 2025 to 2030. The increasing prevalence of chronic conditions such as Benign Prostatic Hyperplasia (BPH) combined with the efforts of several market players to develop laser technologies in order to improve surgical outcomes including reduced turnaround time and minimal hospital stay are the factors driving the market. According to the American Urological Association (AUA), the prevalence of BPH increases with age, with 8.0% in men aged between 31 - 40, to 45.0% in those aged 51 to 60 years and 80.0% in men above 80 years. Also, in August 2018, OmniGuide Holdings acquired Lisa Laser Products, a Germany-based company, which develops lasers for urological applications.
Increasing provisions to address multiple applications through product development, in the field of aesthetics as well as surgery is likely to expand the application in multiple specialties. For instance, in September 2018, Syneron Candela acquired Ellipse, a developer of laser platforms for medical and aesthetic dermatologic applications, in order to strengthen its position in the market.
Surgical Laser Market Report Highlights
- North America accounted for the largest share in 2024 owing to increasing preference for minimally invasive surgical procedures and rising prevalence of chronic diseases in the geriatric population
- By product, gas laser systems are expected to register the highest CAGR during the forecast period
- By application, the aesthetics segment is expected to register the highest market share owing to the increasing availability of cost-effective devices and rising demand for various cosmetic procedures such as resurfacing, rejuvenation, and vascular lesions
- By end-use, the hospital segment accounted for the largest market share as these medical settings incorporate innovative systems for enhancing patient outcomes
- Market players are adopting several strategies such as strategic acquisitions to cater to the increasing patient demand and gain a significant share in the global market.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Disease
- 1.2.3. Regional Scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Disease outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
- Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of target diseases
- 3.2.1.2. Advancements in drug delivery and development
- 3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of anti-VEGF therapeutics
- 3.2.2.2. Potential side effects and safety concerns
- 3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
- 4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Eylea
- 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.6. Lucentis
- 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.7. Beovu
- 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.8. Vabysmo
- 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 4.9. Others
- 4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
- 5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Macular Edema
- 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.6. Diabetic Retinopathy
- 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.7. Retinal Vein Occlusion
- 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.8. Age-related Macular Degeneration
- 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- 5.9. Myopic Choroidal Neovascularization
- 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
- Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis
- 6.1. Regional Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.3. North America
- 6.3.1. U.S.
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Canada
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. Mexico
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework/ reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Germany
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. France
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Italy
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework/ reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.5. Spain
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework/ reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.6. Norway
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework/ reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Regulatory framework/ reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Regulatory framework/ reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. India
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Australia
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Thailand
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Argentina
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. UAE
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Company Categorization
- 7.2. Recent Developments & Impact Analysis by Key Market Participants
- 7.3. Company Market Share Analysis, 2024
- 7.4. Company overview
- 7.4.1. Regeneron Pharmaceuticals, Inc.
- 7.4.1.1. Company Overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Bayer AG
- 7.4.2.1. Company Overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Novartis AG
- 7.4.3.1. Company Overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. F. Hoffmann-La Roche Ltd.
- 7.4.4.1. Company Overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Biogen
- 7.4.5.1. Company Overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. Pfizer, Inc.
- 7.4.6.1. Company Overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Coherus BioSciences, Inc.
- 7.4.7.1. Company Overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. Amgen, Inc.
- 7.4.8.1. Company Overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Bausch Health Companies, Inc.
- 7.4.9.1. Company Overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
- 7.4.10. Viatris, Inc.
- 7.4.10.1. Company Overview
- 7.4.10.2. Financial performance
- 7.4.10.3. Product benchmarking
- 7.4.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook